Cogent Biosciences (COGT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

COGT Cogent Biosciences

Watchlist

7.530
+0.540+7.73%

Close Feb 28 16:00 ET

7.530
0.0000.00%

Post 16:41 ET

857.29MMarket Cap-3.88P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $24
Moomoo NewsFeb 28 12:31 ET · Ratings
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsFeb 28 07:31 ET · Ratings
Cogent Biosciences Reports 2024 Financial Results and Clinical Progress
TipRanksFeb 28 00:09 ET
Express News | Cogent Biosciences Inc : JP Morgan Raises Target Price to $24 From $23
ReutersFeb 27 23:26 ET
Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM
RTTNewsFeb 27 10:03 ET
Baird Maintains Cogent Biosciences(COGT.US) With Hold Rating, Maintains Target Price $8
Moomoo NewsFeb 27 08:31 ET · Ratings

Comments

Peasant Investor

Jan 29 14:03

In with the 🐳📉📉📉

$Cogent Biosciences (COGT.US)$

Wave_Rider

Dec 8, 2024 17:51

Quick AI research

$Cogent Biosciences (COGT.US)$
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...

This_Guy

Dec 8, 2024 17:21

$Cogent Biosciences (COGT.US)$
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...

Trytosaveabit

Dec 8, 2024 16:05

Watching Monday/week! New PR / data released Sunday!

$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients With Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...

Trytosaveabit

Jun 14, 2024 06:37

Update

$Cogent Biosciences (COGT.US)$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions

Trending Stocks

Symbol Mini Chart % Chg

Halozyme Therapeutics

HALO

+2.51%

DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS

DMZPY

+2.27%

Collegium Pharmaceutical

COLL

+2.22%

Unlock the Full List